Narcolepsy in association with pandemic influenza vaccination – a multi-country European epidemiological investigation
This report summarises the results from two epidemiological studies conducted by the Vaccine Adverse Event Surveillance and Communication (VAESCO) Consortium undertaken in eight European Union (EU)/European Economic Area (EEA) countries in order to investigate a possible association between an unexpected increase in narcolepsy cases following the use of influenza A(H1N1)pdm09 vaccines. Narcolepsy is an underdiagnosed disease of widely unknown etiology.
Guide to public health measures to reduce the impact of influenza pandemics in Europe – ‘The ECDC Menu’
This document presents a menu of possible public measures to be taken during influenza pandemics, giving public health and scientific information on what is known or can be said about their likely effectiveness, costs (direct and indirect), acceptability, public expectations and other more practical considerations. The ‘ECDC Menu’ aims to help EU Member States and institutions, individually or collectively, decide which measures they will apply.
Understanding the association between narcolepsy and one of the 2009 adjuvanted influenza A (H1N1) vaccines
This meeting was designed to offer a place to exchange the latest information on into the development of narcolepsy following vaccination with one of the 2009 adjuvanted influenza A(H1N1) vaccines.
Recommendation by the European Medicines Agency concerning Pandemrix vaccination and reports of narcolepsy in children and adolescentsArchived
EMA recommends restricting use in persons under 20 years of age Pandemrix to be used only in the absence of seasonal trivalent influenza vaccines, following link to very rare cases of narcolepsy in young people. Overall benefit-risk remains positive.
Association of childhood narcolepsy and cataplexy and receipt of a pandemic influenza vaccine in Finland in 2009-10 – First papers in a peer review journalArchived
A pair of linked papers from Finland concerning the above topic, one epidemiological and the second combining both clinical and epidemiological were published on March 28th in the open access journal, PLoS One.(1,2).
Report on the association between the 2009 pandemic vaccine (Pandemrix®) and narcolepsy – Republic of IrelandArchived
Investigation of an increase in the incidence of narcolepsy in children and adolescents in 2009 and 2010 - Final Report of National Narcolepsy Study Steering Committee, Department of Health, Ireland
Narcolepsy and Pandemrix Vaccine – an association in adults as well as childrenArchived
In September 2010 Sweden and Finland noted a number of children had developed narcolepsy seemingly in association with having received the pandemic vaccine used almost exclusively in those countries (Pandemrix)
No Serological Evidence of Influenza A H1N1pdm09 Virus Infection as a Contributing Factor in Childhood Narcolepsy after Pandemrix™ Vaccination Campaign in Finland
This is the first published study where an attempt has been made to understand the possible biological mechanisms behind development of narcolepsy following vaccination with Pandemrix™.
EMA's Committee for Medicinal Products for Human Use (CHMP) issues opinion on narcolepsy and vaccination with Pandemrix®Archived
On 21 July 2011 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued its opinion on the review of Pandemrix® and reports on narcolepsy. The CHMP recommended that in persons under 20 years of age Pandemrix® may only be used if the recommended seasonal trivalent influenza vaccine is not available and if immunisation against H1N1 is still needed (e.g. in persons at risk of the complications of infection).